SCOPUS 정보 검색 플랫폼

Journal of Oncology Pharmacy Practice

Volumn 7, Issue 1, 2001, Pages 27-33

Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis

(4) Dranitsaris, George a Castel, Liana D b Baladi, Jean François c Schulman, Kevin A b

a PRINCESS MARGARET HOSPITAL (Canada)

b DUKE UNIVERSITY MEDICAL CENTER (United States)

c Novartis Pharmaceuticals Canada Inc (Canada)

Author keywords

Cost; Pamidronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CANADA; CANCER CENTER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INFUSION; DRUG MANUFACTURE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 0035725585 PISSN: 10781552 EISSN: None Source Type: Journal
DOI: 10.1191/1078155201jp077oa Document Type: Article

Times cited : (9)

References (13)

1
- 0003998061
- eds. 4th ed. Philadelphia: JB Lippincott
- (1993) Cancer: Principles and Practice of Oncology
- Devita, V.T.¹ Hellman, S.² Rosenberg, S.A.³

2
- 0032434254
- Current uses of bisphosphonates in oncology
- (1998) J. Clin. Oncol. , vol.16 , pp. 3890-3899
- Body, J.J.¹ Bartl, R.² Burckhardt, P.³

3
- 0029826473
- The management of malignant hypercalcemia
- (1996) Drugs , vol.52 , pp. 837-848
- Watters, J.¹ Gerrard, G.² Dodwell, D.³

4
- 10544228130
- Efficacy of pamidronate in reducing skeletal events in patients with breast cancer and lytic bone metastases
- (1996) N. Engl. J. Med. , vol.335 , pp. 1785-1791
- Hortobagyi, G.N.¹ Theriault, R.L.² Porter, L.³

5
- 0028823554
- A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
- (1995) Br. J. Cancer , vol.72 , pp. 1289-1293
- Purohit, O.P.¹ Radstone, C.R.² Anthony, C.³ Coleman, R.E.⁴

6
- 0028202499
- Preclinical pharmacology of CGP 42′446, a new potent heterocyclic bisphosphonate compound
- (1994) J. Bone Miner Res. , vol.9 , pp. 745-750
- Green, J.R.¹ Muller, K.² Jaeggi, K.A.³

7
- 0030749323
- Clinical research update: Zoledronate
- (1997) Cancer , vol.80 , pp. 1699-1701
- Body, J.J.¹

8
- 0035863508
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized trials
- (2001) J. Clin. Oncol. , vol.19 , pp. 558-567
- Major, P.¹ Lortholary, A.² Hon, J.³

9
- 0034810866
- A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
- (2001) Support Care Cancer , vol.9 , pp. 545-551
- DesHarnais Castel, L.¹ Bajwa, D.² Markle, J.P.³

10
- 0005865580
- A National List of Provincial Costs for Health Care: Canada 1997/8 Version 1.0
- Institute of Health Economics
- (2000)

11
- 0008627050
- Ontario Health Insurance (OHIP) Schedule of Benefits and Fees: Schedule of Benefits for Physician Services Under the Health Insurance Act
- Ministry of Health and Long-Term Care
- (2001)

12
- 0008677323
- Renal safety and tolerability of 90 mg of Aredia (pamidronate) administered as an intravenous 1 hour infusion: Preliminary results
- (1999) Proc. Am. Soc. Clin. Oncol. , vol.18 , pp. 605a
- Vilimovskij, A.¹ Thuerlimann, B.² Berensen, J.R.³

13
- 85009925265
- Canadian Association of Pharmacy in Oncology (CAPhO)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.